We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
+18%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$21.1M
Cap. Flow
-$3.54M
Cap. Flow %
-1.87%
Top 10 Hldgs %
62.82%
Holding
95
New
10
Increased
16
Reduced
4
Closed
11

Top Buys

Rank Stock Value
1
CLST icon
Catalyst Bancorp
CLST
+$1.84M
2
SPRB
Spruce Biosciences
SPRB
+$1.12M
3
CGEM icon
Cullinan Oncology
CGEM
+$668K
4
INSM icon
Insmed
INSM
+$515K
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$512K

Top Sells

Rank Stock Value
1
CPRX
Catalyst Pharmaceutical
CPRX
+$2.97M
2
ACLX
Arcellx
ACLX
+$2.23M
3
CYTK icon
Cytokinetics
CYTK
+$1.56M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$1.55M
5
TGTX icon
TG Therapeutics
TGTX
+$948K

Sector Composition

Rank Sector Weight
1 Healthcare 52.57%
2 Financials 20.08%
3 Communication Services 17.13%
4 Miscellaneous 7.75%
5 Technology 1.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMO icon
76
Thermo Fisher Scientific
TMO
$230B
$22.6K 0.01%
45
– –
CRM icon
77
Salesforce
CRM
$211B
$12.1K 0.01%
77
– –
STWD icon
78
Starwood Property Trust
STWD
$5.85B
$6.55K ﹤0.01%
400
– –
KD icon
79
Kyndryl
KD
$2.88B
$4.84K ﹤0.01%
428
– –
OXY.WS icon
80
Occidental Petroleum Corp Warrants
OXY.WS
$34.9B
$4.27K ﹤0.01%
+194
New +$6.75K
GEHC icon
81
GE HealthCare
GEHC
$32.4B
$3.2K ﹤0.01%
50
– –
WAB icon
82
Wabtec
WAB
$49.4B
$1.62K ﹤0.01%
6
– –
ACLX
83
DELISTED
Arcellx
ACLX
– –
-19,433
Closed -$2.23M
ADMA icon
84
ADMA Biologics
ADMA
$2.09B
– –
-60,200
Closed -$542K
CNTA
85
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-39,000
Closed -$1.55M
CPRX
86
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-120,000
Closed -$2.97M
CYTK icon
87
Cytokinetics
CYTK
$10B
– –
-23,644
Closed -$1.56M
DD icon
88
DuPont de Nemours
DD
$18.5B
– –
-1,256
Closed -$173K
EOLS icon
89
Evolus
EOLS
$587M
– –
-99,338
Closed -$408K
JSPR icon
90
Jasper Therapeutics
JSPR
$23.3M
– –
-160,789
Closed -$141K
MREO
91
Mereo BioPharma
MREO
$40.3M
– –
-300,337
Closed -$99.1K
LENZ
92
LENZ Therapeutics
LENZ
$161M
– –
-33,732
Closed -$309K
1 2 3
4

Similar funds

GFL
Granite FO LLC Bedford, New Hampshire $189M AUM 56.18% 1-Year Est. Return
SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FSBI
Fearless Solutions (Best Invest) San Antonio, Texas $189M AUM 32.69% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM

David M. Knott Jr's Q2 2026 Portfolio in Review

As of Q2 2026, David M. Knott Jr held 95 positions worth $189M, up 13% from $168M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

David M. Knott Jr's Q2 2026 filing shows 10 new, 16 increased, 4 reduced and 11 closed positions. Its largest new stake was Catalyst Bancorp: 114,000 shares worth $3.58M. The largest sale was Catalyst Pharmaceutical, an estimated $2.97M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 54% a quarter earlier, followed by Financials and Communication Services.

  • David M. Knott Jr's largest Q2 2026 buy was Catalyst Bancorp: 114,000 shares worth $3.58M.
  • David M. Knott Jr added most to Cullinan Oncology in Q2 2026, an estimated $668K increase.
  • David M. Knott Jr's biggest Q2 2026 reduction was TG Therapeutics, cutting an estimated $948K.
  • David M. Knott Jr fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $2.97M.
  • David M. Knott Jr's ten largest holdings make up 63% of its $189M portfolio in Q2 2026.
  • David M. Knott Jr opened 10 new positions and closed 11 in Q2 2026.
  • David M. Knott Jr's portfolio value rose 13% quarter-over-quarter to $189M.

Based on David M. Knott Jr's 13F filing for Q2 2026, filed 12 Aug 2026.